Isatuximab plus bortezomib, lenalidomide, and dexamethasone for transplant-ineligible newly diagnosed multiple myeloma patients: a frailty subgroup analysis of the IMROZ trial - Manier, Salomon; Dimopoulos, Meletios-Athanasios; Leleu, Xavier P.; Moreau, Philippe; Cavo, Michele; Goldschmidt, Hartmut; Orlowski, Robert Z.; Tron, Muriel; Tekle, Christina; Brégeault, Marie-France; Shafer, Andrea T.; Beksac, Meral; et al. (Haematologica, 2025)
Gesehen am 03.02.2026